SELLAS Life Sciences to Host Virtual Investor Symposium on its Lead Asset, Galinpepimut-S, on August 17, 2021
SELLAS Life Sciences Group, a late-stage clinical biopharmaceutical company, will host a virtual investor symposium on August 17, 2021, focusing on its lead asset, galinpepimut-S (GPS). The event will detail GPS's clinical program and recent data regarding acute myeloid leukemia (AML) treatment. Notably, Dr. Yair Levy, a leading cancer researcher, will join the management team. GPS targets the WT1 protein in various tumors and has potential for treating hematologic malignancies and solid tumors.
- None.
- None.
Management Team to be Joined by Leading Cancer Researcher, Dr. Yair Levy, Director of Hematologic Malignancies at the Baylor University Medical Center, and Member of the REGAL Steering Committee
NEW YORK, July 28, 2021 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS" or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, today announced that it will host a virtual investor symposium on its lead asset, galinpepimut-S (GPS), on Tuesday, August 17, 2021, from 1:00 p.m. to 2:00 p.m. ET.
The event will focus on the Company’s clinical program for GPS, including additional details on its recently released clinical data, as well as the significant unmet need in acute myeloid leukemia (AML), the indication being studied in the GPS Phase 3 REGAL study. SELLAS management will be joined by leading cancer researcher, M. Yair Levy, M.D., Director of Hematologic Malignancies at the Baylor University Medical Center, and member of the REGAL Steering Committee.
Dr. Yair Levy serves as the Director of Hematologic malignancies research and specializes in hematology, including lymphoma, myeloma, and leukemia. Dr. Levy received his medical doctorate from the University of Wisconsin at Madison School of Medicine. He served his residency at the University of Pittsburgh Medical Center and his hematology fellowship at Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore, MD. He also served on the faculty at Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Dr. Levy has won several awards, including the ASCO Merit Award, ASH Merit Award, Walsh Research Grant, and the National Institutes of Health LRP Award.
Webcast Information
To attend the live video webcast, please register or email KCSA Strategic Communications at SELLAS@kcsa.com.
About SELLAS Life Sciences Group, Inc.
SELLAS is a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapeutics for a broad range of indications. SELLAS’ lead product candidate, GPS, is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types. GPS has potential both as a monotherapy and in combination to address a broad spectrum of hematologic malignancies and solid tumor indications. SELLAS’ second product candidate, nelipepimut-S (NPS), is a HER2-directed cancer immunotherapy with potential to treat patients with early-stage breast cancer with low to intermediate HER2 expression, otherwise known as HER2 1+ or 2+, which includes triple negative breast cancer patients, following the standard of care.
For more information on SELLAS, please visit www.sellaslifesciences.com.
Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical facts are “forward-looking statements,” including those relating to future events. In some cases, forward-looking statements can be identified by terminology such as “plan,” “expect,” “anticipate,” “may,” “might,” “will,” “should,” “project,” “believe,” “estimate,” “predict,” “potential,” “intend,” or “continue” and other words or terms of similar meaning. These statements include, without limitation, statements related to the clinical development of GPS and the potential for GPS as a drug development candidate. These forward-looking statements are based on current plans, objectives, estimates, expectations, and intentions, and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with the COVID-19 pandemic and its impact on the Company’s clinical plans, risks and uncertainties associated with immune-oncology product development and clinical success thereof, the uncertainty of regulatory approval, and other risks and uncertainties affecting SELLAS and its development programs as set forth under the caption “Risk Factors” in SELLAS’ Annual Report on Form 10-K filed on March 23, 2021 and in its other SEC filings. Other risks and uncertainties of which SELLAS is not currently aware may also affect SELLAS’ forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements herein are made only as of the date hereof. SELLAS undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations or other circumstances that exist after the date as of which the forward-looking statements were made.
Investor Contacts
Valter Pinto / Allison Soss
KCSA Strategic Communications
Email: SELLAS@kcsa.com
Phone: 914.907.2675 / 215.272.2707
Media Contacts
Caitlin Kasunich / Raquel Cona
KCSA Strategic Communications
Email: SELLAS@kcsa.com
Phone: 212.896.1241 / 212.896.1276
FAQ
What is the date of SELLAS Life Sciences Group's investor symposium?
What will be discussed at the SELLAS investor symposium?
Who is Dr. Yair Levy and what is his role in the SELLAS symposium?
What is galinpepimut-S (GPS) and its significance for SELLAS?
Where can I find more information about SELLAS Life Sciences Group?
